The promise of precision oncology

brought to life for patients

KURA REPORTS POSITIVE PRELIMINARY ZIFTOMENIB COMBINATION DATA IN ACUTE MYELOID LEUKEMIA

Preliminary clinical data from the first 20 patients in KOMET-007, a Phase 1 dose-escalation trial of the Company’s potent and selective menin inhibitor, ziftomenib, in combination with standards of care, including cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), in patients with NPM1-mutant and KMT2A-rearranged AML.

SEE THE LATEST KOMET-007 DATA

The promise of precision oncology

brought to life for patients

KURA ANNOUNCES UPDATED CLINICAL DATA PRESENTED AT EHA 2023

Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults with Relapsed/Refractory NPM1-Mutated AML

SEE THE LATEST KOMET-001 DATA

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.

Our novel therapies are designed to target cancer cells selectively, increasing clinical benefit while moving the field forward in areas with the highest unmet needs. Just as vital to our mission, we’re investigating our novel therapies in combination with standards of care, forging new paths to give patients a better chance for long-term durable remissions.

We Are Kura

Our Commitment

We discover and develop novel cancer therapeutics that seek to improve patient outcomes and enable more patients to benefit.

About Us

Our Course

Through our evolving understanding of the molecular processes that drive cancer, we’re pioneering new approaches to treat devastating diseases, including head and neck cancer, lung cancer and acute leukemias.

Pipeline